Oramed Pharmaceuticals has signed an agreement with OnQ consulting, a clinical research organization located in Johannesburg, South Africa, to conduct Phase IIB clinical trials on its oral insulin capsules.
Subscribe to our email newsletter
The study is intended to evaluate the safety, tolerability and efficacy on diabetic type 2 volunteers, using Oramed’s oral insulin capsule.
It is anticipated that this study will be conducted over several months, and the 30 subjects will each receive the treatment for a period of six weeks.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.